PCRX — Pacira BioSciences, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
$27.23
+$0.76 (+2.87%)
Pacira BioSciences, Inc. (PCRX) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by Frank D. Lee, based in 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005, with about 825 employees. Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
Latest reported PCRX revenue for 2025-09-30 was $179.5M. Net income was $5.4M. Revenue was down 0.9% from 2025-06-30 to 2025-09-30. PCRX currently screens at market cap $890.8M and trailing P/E 174.2.
Use this PCRX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PCRX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PCRX SEC filings page. Lician reads the product cache first so this HTML stays unique to Pacira BioSciences, Inc. even when a live quote feed is slow.
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
PCRX Key Statistics
Market Cap
$890.84M
Volume
379,713
Previous Close
$24.86
Day Range
$24.80 – $25.59
P/E Ratio
174.15
P/B Ratio
1.36
EPS
-$2.15
Revenue
$0.00
Net Income
-$99.56M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-100.0%
Employees
825
PCRX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $674.98M | $666.82M | $541.53M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$99.56M | $41.95M | $15.91M | $41.98M |
| EPS (Diluted) | -$2.15 | $0.89 | $0.34 | $0.92 |
Total Assets
$1.55B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$276.77M
Operating Cash Flow
$189.39M
Free Cash Flow
$0.00
Pacira BioSciences, Inc. Company Information
- CEO & Director
- Frank D. Lee
- Headquarters
- 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005
- Website
- www.pacira.com
- Phone
- 650 242 8052
- IPO / Founded
- 2011-02-03
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic